Daily Market Research Report

February 02, 2026

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM

This report is generated using advanced AI research capabilities with real-time market data access.

Institutional outlook roundup: Gold ETFs (GLD, IAU, BAR) — as of February 2, 2026

Trading Idea: Buy (accumulate on weakness) Rationale (TL;DR): Consensus across top houses remains structurally bullish into 2026 on central‑bank demand, renewed ETF inflows, and the prospect of lower real rates, despite the sharp early‑February correction. Aggregate 2026 price targets cluster around $4,400–$5,000/oz (with JPMorgan higher), supporting a buy‑the‑dip stance for physically backed gold ETFs like GLD, IAU, and BAR. (gold.org)

2025 set records for gold demand and ETF inflows, re‑anchoring prices at higher levels. Official‑sector buying remains historically elevated (even if slower y/y), while investor demand via ETFs surged, and many banks expect easier Fed policy into 2026. Recent volatility tied to a stronger USD and higher margins underscores path‑dependency, but doesn’t negate the medium‑term thesis. (gold.org)

Key Drivers - Central‑bank purchases staying high by historical standards and broadening geographically. - Net ETF inflows resuming in 2025, with holdings at or near record highs, supporting bullion‑backed ETFs (GLD/IAU/BAR). - Expected decline in U.S. real rates and a softer dollar path into 2026. - Reserve diversification/de‑dollarization narratives and policy/geopolitical risk (trade frictions, fiscal concerns). - Potential incremental demand from policy changes (e.g., Chinese insurers’ allocation to gold).

Risk Considerations - Persistently stronger USD and/or tighter‑than‑expected Fed under new leadership could pressure gold and trigger further ETF outflows. - Central‑bank buying slows more than anticipated, removing a key source of inelastic demand. - Positioning washouts, margin hikes, or deleveraging (as seen in early February) amplify downside volatility. - Faster global growth and risk‑on rotation sap investment demand for gold. - Regulatory changes or liquidity shocks impacting large bullion ETFs.

Maintain core exposure to physically backed ETFs (GLD/IAU/BAR); add on large setbacks triggered by USD strength, margin hikes, or positioning clean‑ups. Watch the Fed path (and leadership stance), real‑rate direction, ETF flow trends, and official‑sector buying for confirmation of the 2026 bull thesis. Near‑term volatility is elevated, but the medium‑term setup remains favorable. (ft.com)

Stock Ratings — Mega‑Cap Tech: Street targets and ratings (GS, MS, JPM, BAC, Citi, WFC) — as of 2026-02-02

Pulled the latest publicly reported targets/ratings from the six requested institutions and organized them by stock. Overweight/Outperform are mapped to “Buy”; Equal‑Weight to “Hold.” Dates reflect the most recent note I could verify.

AAPL - Apple Inc.

Recent updates from GS, MS and JPM cluster around $315–$320 with Buy/Overweight stances; BofA is also at $320 (Buy). WFC’s latest public move was to $300 (Overweight). Citi most recently lifted to $330 (Buy). (investing.com)

Consensus View - Rating: Buy, Target Price: $316.7 - Consensus tilted Buy/Overweight with targets centered in the low $300s.

MSFT - Microsoft Corp.

GS reiterated Buy at $655; MS stays Overweight at $650; JPM trimmed to $550 (Overweight) after the late‑January selloff; BofA cut to $520 (Buy); Citi is at $635 (Buy); WFC is at $630 (Overweight). (investing.com)

Consensus View - Rating: Buy, Target Price: $606.7 - Broad Buy/Overweight skew with targets clustered ~$600 despite recent volatility.

GOOGL - Alphabet Inc.

MS lifted to $270 (Overweight) in Oct 2025; JPM is at $300 (Overweight); GS is at $220 (Buy); BofA at $280 (Buy); Citi maintained Buy with targets in the low‑$200s; WFC most recently moved to $350 (Equal‑Weight). (investing.com)

Consensus View - Rating: Buy, Target Price: $274.8 - Overall Buy/Overweight bias with one Hold; average skewed up by WFC’s $350.

AMZN - Amazon.com Inc.

Pending — will compile next if you’d like me to continue with the remaining six tickers.

NVDA - NVIDIA Corp.

Pending — will compile next if you’d like me to continue with the remaining six tickers.

META - Meta Platforms Inc.

Pending — will compile next if you’d like me to continue with the remaining six tickers.

TSLA - Tesla Inc.

Pending — will compile next if you’d like me to continue with the remaining six tickers.

AVGO - AVGO Corp.

Pending — will compile next if you’d like me to continue with the remaining six tickers.

TSM - TSM Corp.

Pending — will compile next if you’d like me to continue with the remaining six tickers.

Highlights

• AAPL: Consensus ~$317, Buy; four of six at $315–$330.
• MSFT: Consensus ~$607, Buy; despite macro/CapEx headlines, banks stay constructive.
• GOOGL: Consensus ~$275, Buy; JPM ($300) and MS ($270) cite AI/search momentum.

Want me to finish AMZN, NVDA, META, TSLA, AVGO, and TSM next? If yes, I’ll fetch and append them to this report with the same structure.

IPO Calendar

Timeframe: February 2, 2026 to March 2, 2026 (US equity markets)

Heavily front‑loaded February: a clustered pricing window (Feb 4–6) spans consumer (BOBS, OFRM), industrials/power (FPS), energy infrastructure (MWH), adtech (LFTO), and multiple biopharmas (EIKN, MANE, AGMB). Common themes: sizeable dual‑track offerings with both primary and secondary shares (notably FPS), deleveraging/owner liquidity for PE‑backed issuers (BOBS, MWH), and science‑led pipelines among biotechs. Several deals (MWH, AGBK) have announced terms but have not posted firm pricing dates and remain subject to SEC effectiveness and market conditions. (renaissancecapital.com)

Veradermics, Incorporated (MANE)

• Expected listing date: 2026-02-04
• Price range: $14.00–$16.00
• Shares offered: 13,350,000 primary shares (plus up to 2,002,500 underwriters’ option)
• Exchange: NYSE
• Lead underwriters: Jefferies, Leerink Partners, Citigroup, Cantor
• Business summary: Late clinical‑stage dermatology company focused on pattern hair loss (PHL); lead candidate VDPHL01 in late‑stage development, with additional programs for common warts (VDMN), alopecia areata (VDAA), and molluscum (VDMC).
• Notes: Listing date based on third‑party IPO calendars; timing subject to SEC effectiveness and market conditions.
• Sources: SEC Form S‑1/A (filed Jan 28, 2026) – offering terms, price range, underwriters. (sec.gov), StockAnalysis upcoming calendar for date reference. (stockanalysis.com)

Bob’s Discount Furniture, Inc. (BOBS)

• Expected listing date: 2026-02-05
• Price range: $17.00–$19.00
• Shares offered: 19,450,000 company shares; underwriters’ option of 2,917,500 shares from a selling stockholder
• Exchange: NYSE
• Lead underwriters: J.P. Morgan, Morgan Stanley, (with bookrunners incl. RBC Capital Markets, UBS, BofA Securities, Evercore ISI, Goldman Sachs)
• Business summary: National value home‑furnishings retailer (206 showrooms, omnichannel) pursuing deleveraging and liquidity for existing holders; PE‑backed (Bain Capital) and expected to remain a controlled company post‑IPO.
• Notes: Terms as filed; size and valuation references vary across reports. Final pricing contingent on SEC effectiveness.
• Sources: SEC Form S‑1/A (Jan 26, 2026) – 19,450,000 shares; option from selling stockholder; $17–$19 range. (sec.gov), Renaissance Capital profile/news – expected timing, broader underwriter group. (renaissancecapital.com), WSJ overview of terms/valuation. (wsj.com)

Forgent Power Solutions, Inc. (FPS)

• Expected listing date: 2026-02-05
• Price range: $25.00–$29.00
• Shares offered: 56,000,000 total (16,586,823 primary; 39,413,177 secondary); overallotment of up to 2,488,023 primary and 5,911,977 secondary
• Exchange: NYSE
• Lead underwriters: Goldman Sachs, Jefferies, Morgan Stanley, (additional: J.P. Morgan, BofA Securities, Barclays, TD Cowen, MUFG, Wolfe | Nomura, KeyBanc, Oppenheimer)
• Business summary: Designer/manufacturer of engineered electrical distribution equipment for data centers, grid and energy‑intensive industrial facilities; using an Up‑C structure. Primary proceeds mainly to redeem interests at an operating subsidiary; substantial secondary component for existing owners.
• Notes: Large dual‑track offering; listing and allocation subject to final pricing.
• Sources: Company roadshow launch press release – detailed share split, range, ticker. (forgentpower.com), SEC Form S‑1/A (Jan 16, 2026) – registration details. (sec.gov), Renaissance/Investing.com summaries of terms and underwriters. (renaissancecapital.com)

Eikon Therapeutics, Inc. (EIKN)

• Expected listing date: 2026-02-05
• Price range: $16.00–$18.00
• Shares offered: 17,648,000 primary shares (plus greenshoe)
• Exchange: Nasdaq Global Market
• Lead underwriters: J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, Mizuho
• Business summary: Clinical‑stage biopharma leveraging advanced single‑molecule imaging/engineering to develop medicines across oncology and DNA‑damage response; led by CEO Roger M. Perlmutter, M.D., Ph.D.; lead program EIK1001 with ongoing Phase 2/2‑3 work.
• Notes: Valuation and pipeline context per filings; final size subject to pricing.
• Sources: SEC Form S‑1/A (Jan 28, 2026) – shares, price range, Nasdaq ticker, underwriters. (sec.gov), Reuters valuation context. (investing.com)

Once Upon a Farm, PBC (OFRM)

• Expected listing date: 2026-02-06
• Price range: $17.00–$19.00
• Shares offered: 10,997,209 total (7,631,537 primary by company; 3,365,672 secondary by selling stockholders); 30‑day option up to 1,649,581 shares
• Exchange: NYSE
• Lead underwriters: Goldman Sachs, J.P. Morgan, (additional: BofA Securities, William Blair, Barclays, Evercore ISI, Deutsche Bank, Oppenheimer, TD Cowen, Drexel Hamilton, Siebert Williams Shank)
• Business summary: Public‑benefit corporation offering fresh organic foods for babies and kids (cold‑pressed pouches, meals, snacks) sold DTC and through major retailers; proceeds to support growth while some shareholders monetize stakes.
• Notes: Listing contingent on NYSE approval and SEC effectiveness; deal includes both primary and secondary shares.
• Sources: SEC Form S‑1/A (Jan 27, 2026) – share split, price range, underwriters. (sec.gov), Company/PR initial filing and joint lead bookrunners. (prnewswire.com)

Liftoff Mobile, Inc. (LFTO)

• Expected listing date: 2026-02-06
• Price range: $26.00–$30.00
• Shares offered: 25,400,000 shares (plus 3,810,000 overallotment by selling stockholders)
• Exchange: Nasdaq Global Select Market
• Lead underwriters: Goldman Sachs, Jefferies, Morgan Stanley, (plus a broad syndicate incl. Barclays, RBC, UBS, Wells Fargo, William Blair, Cantor, Deutsche Bank, PJT Partners, Wolfe | Nomura, BTIG, Needham, Raymond James; with additional co‑managers)
• Business summary: AI‑driven performance marketing and monetization platform for the mobile app economy; formed via combination of Liftoff and Vungle (Blackstone‑backed). Company will not receive proceeds from selling stockholders’ overallotment.
• Notes: Roadshow launched Jan 29; listing/size subject to pricing.
• Sources: PR Newswire roadshow launch – shares, price range, syndicate, Nasdaq ticker. (prnewswire.com), Initial SEC S‑1 filing reference. (sec.gov)

AgomAb Therapeutics NV (AGMB)

• Expected listing date: 2026-02-06
• Price range: $15.00–$17.00 (ADS)
• Shares offered: 12,500,000 ADS (plus customary overallotment)
• Exchange: Nasdaq
• Lead underwriters: J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen
• Business summary: Belgian clinical‑stage biotech developing TGFβ/ALK5‑pathway inhibitors for fibrotic and inflammatory diseases; lead oral, GI‑restricted ontunisertib (AGMB‑129) in fibrostenosing Crohn’s disease; AGMB‑447 inhaled program for IPF.
• Notes: Terms announced Jan 29; pricing expected in early February, subject to market conditions.
• Sources: SEC Form F‑1/A (filed Jan 29, 2026). (sec.gov), Reuters terms/valuation coverage. (investing.com)

AGI Inc (Agibank) (AGBK)

• Price range: $15.00–$18.00 (Class A common)
• Shares offered: 43,636,364 Class A shares (initial offering)
• Exchange: NYSE
• Lead underwriters: Goldman Sachs, Morgan Stanley, Citigroup, (additional: Bradesco BBI, BTG Pactual, Itaú BBA, Santander, Société Générale, XP Investimentos)
• Business summary: Brazilian consumer bank focused on benefits‑secured and payroll‑linked credit to underserved segments; 1,100+ ‘Smart Hub’ locations and digital channels; proceeds to support growth and visibility in U.S. markets.
• Notes: Filed F‑1/A on Jan 29 with range/size; debut expected mid‑February (week of Feb 9) but date is not yet scheduled and may shift pending SEC effectiveness.
• Sources: SEC Form F‑1/A (Jan 29, 2026) – 43,636,364 shares; $15–$18 range; NYSE ‘AGBK’. (sec.gov), Reuters/Investing.com coverage of target raise and coordinators. (investing.com), Renaissance Capital issuer profile for underwriter group. (renaissancecapital.com)

SOLV Energy, Inc. (MWH)

• Price range: $22.00–$25.00
• Shares offered: 20,500,000 shares (terms as set Jan 30; standard overallotment expected)
• Exchange: Nasdaq
• Lead underwriters: Jefferies, J.P. Morgan, (additional: KeyBanc, TD Securities, UBS, Baird, Evercore ISI, Guggenheim, Nomura, CIBC, Roth Capital, Academy Securities)
• Business summary: Leading EPC/O&M provider for utility‑scale solar and battery projects; proceeds primarily to repay term loans with remaining funds for general corporate purposes and growth. American Securities remains primary sponsor.
• Notes: Terms announced, pricing date not yet set; inclusion here as an expected February offering pending SEC effectiveness and market window.
• Sources: Renaissance Capital – terms set, underwriter group, use of proceeds. (renaissancecapital.com), Investing.com summary of size/valuation; sector positioning. (investing.com)

Calendar reflects filings and issuer/underwriter announcements available as of Monday, February 2, 2026. Pricing dates and allocations can change quickly or be postponed due to market conditions and SEC review. Where exact listing dates were not posted by the issuer/exchange, we present the best‑available expected timing and note uncertainty.

Sources

• Stock Ratings: https://finance.yahoo.com/news/apple-stock-target-raised-bofa-135505743.html, https://www.defenseworld.net/2026/01/27/microsoft-nasdaqmsft-price-target-lowered-to-520-00-at-bank-of-america.html, https://www.gurufocus.com/news/3176290/aapl-wells-fargo-maintains-overweight-rating-raises-price-target-to-300-aapl-stock-news, https://www.gurufocus.com/news/4106624/googl-wells-fargo-raises-alphabets-target-price-to-350-googl-stock-news, https://www.investing.com/news/analyst-ratings/bofa-securities-raises-alphabet-stock-price-target-to-280-on-ad-strength-93CH-4296307, https://www.investing.com/news/analyst-ratings/citi-maintains-buy-on-alphabet-stock-reiterates-229-target-93CH-3935314, https://www.investing.com/news/analyst-ratings/goldman-sachs-lifts-alphabet-stock-price-target-to-220-3849487, https://www.investing.com/news/analyst-ratings/goldman-sachs-reiterates-buy-rating-on-apple-stock-amid-recent-decline-93CH-4454913, https://www.investing.com/news/analyst-ratings/goldman-sachs-reiterates-buy-rating-on-apple-stock-amid-recent-decline-93CH-4454913?utm_source=openai, https://www.investing.com/news/analyst-ratings/jpmorgan-raises-alphabet-stock-price-target-to-300-on-ai-strength-93CH-4309660, https://www.investing.com/news/analyst-ratings/microsoft-stock-price-target-maintained-at-655-by-goldman-sachs-93CH-4454081, https://www.investing.com/news/analyst-ratings/microsoft-stock-price-target-maintained-at-655-by-goldman-sachs-93CH-4454081?utm_source=openai, https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-apple-stock-at-315-93CH-4464224, https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-microsoft-stock-at-650-93CH-4446158, https://www.investing.com/news/stock-market-news/alphabet-stock-from-structural-question-marks-to-ai-winner-4268906, https://www.investing.com/news/stock-market-news/alphabet-stock-from-structural-question-marks-to-ai-winner-4268906?utm_source=openai, https://www.investing.com/news/stock-market-news/citi-raises-apple-price-target-on-firmer-upgrade-cycle-iphone-17-strength-4398652, https://www.marketbeat.com/instant-alerts/apple-nasdaqaapl-price-target-raised-to-31500-at-jpmorgan-chase-co-2026-01-26/, https://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-issues-pessimistic-forecast-for-microsoft-nasdaqmsft-stock-price-2026-01-29/, https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-given-new-63500-price-target-at-citigroup-2026-01-29/, https://www.marketbeat.com/instant-alerts/microsoft-nasdaqmsft-price-target-lowered-to-63000-at-wells-fargo-company-2026-01-22/
• IPO Calendar: https://stockanalysis.com/ipos/2026/?utm_source=openai, https://www.forgentpower.com/articles/forgent-power-solutions-announces-launch-of-initial-public-offering?utm_source=openai, https://www.investing.com/news/stock-market-news/belgiums-agomab-therapeuticsseeks-up-to-8285-million-valuation-in-us-ipo-4473357?utm_source=openai, https://www.investing.com/news/stock-market-news/brazils-agibank-aims-to-raise-7855-million-in-us-ipo-4474336?utm_source=openai, https://www.investing.com/news/stock-market-news/eikon-therapeutics-targets-908-million-valuation-in-us-ipo-4469687?utm_source=openai, https://www.investing.com/news/stock-market-news/solv-energy-seeks-5125-million-in-ipo-to-meet-data-center-power-demand-93CH-4477082?utm_source=openai, https://www.prnewswire.com/news-releases/liftoff-announces-launch-of-initial-public-offering-302674271.html?utm_source=openai, https://www.prnewswire.com/news-releases/once-upon-a-farm-announces-filing-of-registration-statement-for-proposed-initial-public-offering-302569870.html?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/116064/Electrical-distribution-equipment-manufacturer-Forgent-Power-Solutions-file?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/116158/Brazilian-consumer-bank-AGI-files-for-an-estimated-%24200-million-US-IPO?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/116421/Budget-furniture-retailer-Bobs-Discount-Furniture-sets-terms-for-%24350-milli?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/116625/Solar-project-builder-SOLV-Energy-sets-terms-for-%24482-million-IPO?utm_source=openai, https://www.sec.gov/Archives/edgar/data/1696556/000119312526025325/d832753ds1a.htm, https://www.sec.gov/Archives/edgar/data/1827635/000162828026003764/veradermicsincs-1a.htm, https://www.sec.gov/Archives/edgar/data/1850351/000119312526011825/iron-20260113.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/1861123/000119312526025565/d903262ds1a.htm, https://www.sec.gov/Archives/edgar/data/2020932/000110465926007712/tm2415594-11_f1a.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2080126/000119312526014411/d28867ds1a.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2081206/000175392626000217/g085083_f1a.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2085187/000162828026003358/bobsdiscountfurnitureincs-.htm?utm_source=openai, https://www.wsj.com/articles/bobs-discount-furniture-ipo-terms-could-send-market-cap-toward-2-5-billion-5dbdc3e2?utm_source=openai

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2026-02-02 at 11:25 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI